📄 Extracted Text (424 words)
Subject: Re: quick discussion about pharma financing opportunity? [C]
From: Paul Morris a>
Date: Sat, 16 May 2015 08:40:21 -0400
To: [email protected]
Classification: Confidential
Will circle back if we move forward
Tx
From: jeffrey E. [mailto:[email protected]]
Sent: Thursday, May 14, 2015 12:21 PM
To: Paul Morris
Subject: Re: quick discussion about pharma financing opportunity? [C]
yes interested
On Thu, May 14, 2015 at 12:07 PM, Paul Morris a wrote:
Classification: Confidential
jeffrey, we are working on a live situation with a pharma company that is
looking to finance the distribution and sales of a newly approved drug. DB
is bidding on the debt financing and would need to syndicate out —$50mm to a
third party. I expect the transaction to be structured as a royalty
arrangement and imagine yields would be in the low double digits. I know
you've done equity transactions in biotech area over the years but thought
you may have someone interested in a discussion with our structured credit
team to see if this would be a fit? Let's catch up soon.
Hope all is well,
Paul Morris
Managing Director
Deutsche Bank Private Bank
EFTA01462733
Office:
Cell:
fcid:[email protected]
Securities offered through Deutsche Bank Securities Inc.
This communication may contain confidential and/or privileged information.
If you are not the intended recipient (or have received this communication
in error) please notify the sender immediately and destroy this
communication. Any unauthorized copying, disclosure or distribution of the
material in this communication is strictly forbidden.
Deutsche Bank does not render legal or tax advice, and the information
contained in this communication should not be regarded as such.
please note
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
JEE
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA01462734
This communication may contain confidential and/or privileged information.
If you are not the intended recipient (or have received this communication
in error) please notify the sender immediately and destroy this
communication. Any unauthorized copying, disclosure or distribution of the
material in this communication is strictly forbidden.
Deutsche Bank does not render legal or tax advice, and the information
contained in this communication should not be regarded as such.
EFTA01462735
ℹ️ Document Details
SHA-256
5540aad82f5c434b1bebc9d9e6664046e9e7e3d232214c5deadf7998142d45cf
Bates Number
EFTA01462733
Dataset
DataSet-10
Document Type
document
Pages
3
Comments 0